- Home
- AVTE vs NSPR Comparison
AVTE vs NSPR Comparison
Compare AVTE & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTE
- NSPR
- Stock Information
- Founded
- AVTE 2018
- NSPR 2005
- Country
- AVTE United States
- NSPR Israel
- Employees
- AVTE N/A
- NSPR N/A
- Industry
- AVTE Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- AVTE Health Care
- NSPR Health Care
- Exchange
- AVTE Nasdaq
- NSPR Nasdaq
- Market Cap
- AVTE 72.5M
- NSPR 75.6M
- IPO Year
- AVTE 2021
- NSPR N/A
- Fundamental
- Price
- AVTE $2.51
- NSPR $2.69
- Analyst Decision
- AVTE Hold
- NSPR Strong Buy
- Analyst Count
- AVTE 7
- NSPR 2
- Target Price
- AVTE $11.75
- NSPR $4.75
- AVG Volume (30 Days)
- AVTE 62.3K
- NSPR 67.4K
- Earning Date
- AVTE 03-27-2025
- NSPR 03-12-2025
- Dividend Yield
- AVTE N/A
- NSPR N/A
- EPS Growth
- AVTE N/A
- NSPR N/A
- EPS
- AVTE N/A
- NSPR N/A
- Revenue
- AVTE N/A
- NSPR $7,009,000.00
- Revenue This Year
- AVTE N/A
- NSPR $50.18
- Revenue Next Year
- AVTE N/A
- NSPR $159.56
- P/E Ratio
- AVTE N/A
- NSPR N/A
- Revenue Growth
- AVTE N/A
- NSPR 12.96
- 52 Week Low
- AVTE $1.25
- NSPR $1.81
- 52 Week High
- AVTE $32.42
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- AVTE 52.00
- NSPR 39.79
- Support Level
- AVTE $2.44
- NSPR $2.57
- Resistance Level
- AVTE $2.56
- NSPR $2.78
- Average True Range (ATR)
- AVTE 0.09
- NSPR 0.20
- MACD
- AVTE 0.00
- NSPR -0.01
- Stochastic Oscillator
- AVTE 77.14
- NSPR 17.72
Stock Price Comparison Chart: AVTE vs NSPR
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.